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INTRODUCTION
Aspirin (acetylsalicylic acid, ASA) sensitivity results in
distinct clinical syndromes. Patients sensitive to ASA usually
develop either a respiratory syndrome (ASA-intolerant asth-
ma, AIA) or a cutaneous syndrome (ASA-intolerant urticaria/
angioedema, AIU) (1, 2). ASA is also an occasional cause of
anaphylaxis (3). 
The pathogenesis of ASA sensitivity most likely involves
inhibition of cyclooxygenase by ASA or other nonsteroidal
anti-inflammatory drugs (NSAIDs) resulting in an enhanced
production of leukotrienes (LTs), potent inflammatory medi-
ators synthesized from arachidonic acid through a sequen-
tial pathway. It is widely recognized that LT biosynthesis is
associated with the development and progression of AIA.
Urinary LT E4 excretion is higher in patients sensitive to
ASA than in patients insensitive to ASA (4, 5). Drugs that
inhibit the synthesis of LT have clinical efficacy in asthma
(6, 7).
In contrast to AIA, the study of the cutaneous reaction
resulting from ASA sensitivity has not yet led to understand-
ing of the mechanism underlying this reaction. Many patients
with chronic urticaria exhibit increased wheal and swelling
after intake of ASA (2, 8). The proportion of patients with
chronic urticaria who develop exacerbation after ASA admin-
istration ranges from 20% to 30% (1), whereas ASA admin-
istration causes urticaria and/or angioedema in a percentage
ranging from 1% to 6% of normal subjects (9). The mecha-
nisms of such hypersensitivity to ASA are still poorly under-
stood. It has been postulated that ASA sensitivity may be
caused by a mechanism with increased production of cysteinyl-
LT (10) as the pathogenesis of AIA. This suggestion is streng-
thened by several reports that antihistamine, histamine recep-
tor 1 antagonist, may not be sufficient as a monotherapy in
urticaria sensitive to ASA and LT receptor antagonist (LTRA)
may be effective in chronic urticaria (11-14). It has been re-
ported that cyclooxygenase-2 (COX2) inhibitor may be given
safely to patients with AIU (15, 16). In patients with chronic
urticaria, baseline urinary LT E4 excretion is higher in patients
sensitive to ASA than in patients insensitive to ASA (1). These
Seung-Hyun Kim, Jeong-Hee Choi, 
J. W. Holloway*, Chang-Hee Suh, 
Dong-Ho Nahm, Eun-Ho Ha
� , 
Choon-Sik Park
� , Hae-Sim Park
Department of Allergy and Rheumatology, Ajou 
University School of Medicine, Suwon, Korea; Human
Genetics Division*, University of Southampton School
of Medicine, Southampton, U.K.; Department of 
Statistics, Yonsei University
� , Seoul; Asthma Genome
Research Center
� , Soonchunhyang University,
Bucheon, Korea
Address for correspondence
Hae-Sim Park, M.D.
Department of Allergy and Rheumatology, Ajou 
University School of Medicine, San-5 Wonchondong,
Yeongtong-gu, Suwon 442-721, Korea
Tel : +82.31-219-5196, Fax : +82.31-219-5154
E-mail : hspark@ajou.ac.kr 
*This study was supported by a grant of the Korea
Health 21 R &D project. Ministry of Health & Welfare,
Republic of Korea (01-PJ10-PG6-01GN14-0002).
926
J Korean Med Sci 2005; 20: 926-31
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Leukotriene-related Gene Polymorphisms in Patients with
Aspirin-intolerant Urticaria and Aspirin-intolerant Asthma: Differing
Contributions of ALOX5 Polymorphism in Korean Population
The pathogenesis of aspirin (acetylsalicylic acid, ASA)-intolerant urticaria (AIU) is
still poorly understood but it has recently been suggested that it is associated with
the overproduction of leukotriene (LT). This is supported by evidence that cyclooxy-
genase 2 inhibitor is given safely to patients with AIU. The present study was designed
to investigate the role of genetic polymorphism of LT related genes in the pathogen-
esis of AIU via a case-control study. We screened single nucleotide polymorphisms
(SNPs) in genes encoding enzymes involved in leukotriene synthesis in the Korean
population with AIU (n=101), ASA-intolerant asthma (AIA, n=95) and normal healthy
controls (n=123). Genotype was determined by primer extension reactions using
the SNapShot ddNTP primer extension kit. Among 8 SNPs of four LT related genes,
the polymorphism of ALOX5 at positions of -1708 G>A showed significant difference
in genotype frequency between AIU and AIA (p=0.01). Furthermore, there were
significant differences observed in the frequencies of two ALOX5 haplotypes between
the AIU group and AIA group (p<0.05). However, there were no differences in allele,
genotype, or haplotype frequencies of ALOX5 between the AIU group and the nor-
mal control group. These results suggested that ALOX5 has a differing contribution
in two major clinical pathogenesis related to ASA-sensitivity. 
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studies support the hypothesis that overproduction of LT may
be important in chronic urticaria.
Although there is no clear evidence of the involvement of
LT in AIU and/or angioedema, it has been proposed that LTs
may participate in the pathogenesis of urticaria and angio-
edema in a similar mechanism to that of AIA. We (17) and
others (18, 19) have previously shown that polymorphism
in LT related genes is associated with AIA. Therefore, there
is a rationale to investigate the genetic polymorphisms of
candidate genes related with LT production in AIU and/or
angioedema. 
In this study, we investigated the genetic polymorphism
in 8 candidate single nucleotide polymorphisms (SNPs) of
four LT related genes, ALOX5 (5-lipoxygenase), ALOX5AP
(5-lipoxygenase activating protein), PTGS2 (cyclooxygenase
2) and LTC4S (LTC4 synthase), in patients with AIU com-
pared to AIA and a normal healthy control group recruited
from a Korean population 
MATERIALS AND METHODS
Study subjects
One hundred one patients with urticaria sensitive to both
ASA and NSAIDs (46 male subjects; mean age: 34.2 yr; 31
patients had underlying chronic urticaria with more than 6
weeks duration), 95 patients with ASA-intolerant asthma (35
male subjects, mean age: 42.3 yr), and 123 normal healthy
controls (NC) enrolled from the Department of Allergy and
Rheumatology, Ajou University Hospital, Suwon, Korea were
enrolled in the study. In this study, ASA-intolerant urticaria
group was defined as patients having a certain history of ur-
ticaria/angioedema development after the ingestion of more
than two kinds of NSAIDs and positive responders on oral ASA
challenge test (classified as cross reacting group by Sanchez-
Borges et al. (20)). Also NSAIDs sensitivity could be confirm-
ed because the patients visited our Allergy Clinic or emer-
gency room presenting current urticaria/angioedema after
taking NSAIDs. In order to exclude a single ASA-intolerant
urticaria, we performed skin prick test with 10 mg/mL of
lysine-ASA (L-ASA) and none of them had positive skin prick
test. ASA-intolerant asthma was diagnosed by a positive result
to L-ASA bronchoprovocation testing and they had no history
of drug allergies presenting as skin manifestations. Patients
having both AIA and AIU were excluded in this study. 123
normal controls, who had non-atopy, no personal and family
history of allergic diseases, and no past history of ASA and
other drug hypersensitivity, were recruited from the general
population. Seventy (77.8%) patients among the ASA-intol-
erant urticaria group and 35 (43.8%) in ASA-intolerant asth-
ma patients were atopic. All subjects provided informed con-
sent and the protocol used were approved by the ethics com-
mittee of Ajou University Hospital, Suwon, Korea. Skin prick
tests were performed with 12 common aeroallergens (Bencard
Co., U.K.) including Dermatophagoides pteronyssinus, Dermato-
phagoides farinae, cat, dog, cockroach, tree pollen mixture, grass
pollen mixture, mugwort, ragweed, Hop Japanese, Aspergillus,
Alternaria, with histamine and saline controls. 
Oral ASA challenge and L-ASA bronchoprovocation tests
All medications, including theophyllines, beta-2 agonists,
LT receptor antagonist, anti-histamine and steroids were
stopped 72 hr before the procedure. After the placebo chal-
lenge, 500 mg of ASA in a tablet was orally administered,
and patients were observed for 4 hr with monitoring of urticaria
and changes of lung functions every 30 min. Appearance of
urticaria within 4 hr without any changes of FEV1 was con-
sidered as a positive result. L-ASA bronchoprovocation test
was performed according to the modified method as previ-
ously described (17, 21). The test solutions were delivered
by a DeVilbiss 646 nebulizer (DeVilbiss Co., Somerset, Penn.,
U.S.A.) and connected to a compressed air source (5 L/min).
L-ASA powder (Althargyl
�, Arthromedica, Swiss) that con-
tained 900 mg L-ASA with 100 mg aminoacetic acid was
diluted in normal saline to produce a stock solution of 300
mg/mL. A placebo solution of normal saline was used as a
control. Subjects inhaled the aerosol via a mouthpiece dur-
ing normal tidal breathing. The L-ASA solution was inhaled
every 30 min. The FEV1 and maximum mid expiratory flow
(MMEF) are measured at 10 and 30 min after each dose. The
provocation was stopped when the FEV1 has decreased 20%
or more from the baseline. The FEV1 and MMEF after the
last dose were measured at 10, 30, 60 min, and then hourly
for 7 hr.
AIU
(n=101)
AIA
(n=95)
NC
(n=123)
Age (yr)* 34.2±12.3 42.3±14.1 35.2±14.9
Sex (M) 46 (45.5%) 35 (36.8%) 63 (51.2%)
Atopy
� 70 (77.8%) 35 (43.8%) 19 (16.7%)
Total IgE  333.4±366.7 346.6±460.0 70.0±71.1
History of other 9 (8.9%) NA 0
drug allergy
History of allergic  57 (51.5%) NA 0
diseases
Provocation test 28 (27.7%) 76 (80.0%) NA
Urticaria 42 (41.5%) 0 NA
Angioedema 18 (17.8%) 0 NA
Urti/angio. 41 (40.5%) 0 NA
Anaphylaxis 4 (4.0%) 0 NA
Chronic urticaria 31 (30.7%) 0 NA
Table 1. Clinical characteristics of the study subjects
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal
controls; NA, not applicable. 
*p<0.01 (AIU vs. AIA). 
� p<0.01 (AIU vs. AIA and AIU vs. NC). 928 S.-H. Kim, J.-H. Choi, J.W. Holloway, et al.
Genomic DNA preparation and SNP genotyping
Peripheral blood samples (10 mL) were collected from study
subjects. Genomic DNA was extracted using a G-DEXTM
for Blood Genomic DNA Extraction Kit (iNtRON Biotech-
nology, Korea) according to the manufacturer’s instructions.
For each of the 8 SNPs in the four genes, ALOX5, ALOX5AP,
PTGS2 and LTC4S, analyzed, pairs of forward and reverse
primers were designed to amplify the genomic region sur-
rounding the SNP of interest (Table 1). The polymerase chain
reaction (PCR) was performed with 20 ng genomic DNA,
50 mM KCl, 10 mM Tris, 2 mM MgCl2, 1.25 pmol of each
primer, 200  M dNTPs, and 0.15 U Taq DNA polymerase
(Perkin Elmer, Emeryville, CA, U.S.A.) in standard buffer
provided by the manufacturer. After initial denaturation for
5 min at 95℃, a touch-down PCR (22) was undertaken with
10 cycles consisting of 1 min denaturation at 94℃, 1 min
annealing at 54℃ and 2 min elongation at 72℃ followed
by 35 cycles of 1 min at 94℃, 1 min at 45℃ and 2 min at
72℃. A final elongation step at 72℃for 10 min terminated
the program. Primer extension reactions were performed with
the SNaPSHOT ddNTP primer extension kit (Applied Bio-
systems) as recommend by the manufacturer using extension
probes as previously described (17). 
Data analysis
Statistical analyses were completed using SPSS version 10
(SPSS Inc., Chicago, IL, U.S.A.) and a p-value <0.05 was con-
sidered to be significant. Allele frequencies were calculated
for each polymorphic site by the allele counting method,
and significant departures of genotype frequency from the
Hardy-Weinberg equilibrium (HWE) at each polymorphic
site were tested by chi-square analysis. Differences in geno-
type frequency between patients and controls were tested by
Fisher’s exact test. Differences in the mean value of the phe-
notypic characteristics within patient groups were compared
using ANOVA and t-test. Haplotypes of ALOX5 were ana-
AIU (n=101) AIA (n=95) NC (n=123)
p value*
AIU vs. AIA AIU vs. NC
Locus Genotype Gene
ALOX5 -1708G>A GG 57 (56.4%) 48 (64.9%) 76 (67.9%) 0.04 NS
AG 33 (32.7%) 25 (33.8%) 30 (26.8%) 0.01 NS
AA 11 (10.9%) 1 (1.4%) 6 (5.4%) NS NS
q. 0.272 0.182 0.188 0.06 0.04
270G>A GG 92 (91.1%) 72 (90.0%) 98 (85.2%) NS NS
AG 9 (8.9%) 8 (10.0%) 16 (13.9%) NS NS
AA 0 0 1 (0.9%) NS NS
q. 0.045 0.05 0.078 NS NS
1728A>G AA 80 (81.6%) 71 (92.21%) 98 (86.0%) NS NS
AG 17 (17.3%) 6 (7.8%) 16 (14.0%) NS NS
GG 1 (1.0%) 0 0 0.05 NS
q. 0.097 0.039 0.07 0.04 NS
ALOX5AP 218A>G AA 99 (98.0%) 90 (98.9%) 119 (98.3%) NS NS
AG 2 (2.0%) 1 (1.1%) 2 (1.7%) NS NS
GG 0 0 0 NS NS
q. 0.01 0.005 0.008 NS NS
PTGS2 -162C>G CC 95 (96.9%) 86 (98.9%) 114 (96.6%) NS NS
CG 3 (3.1%) 1 (1.1%) 4 (3.4%) NS NS
GG 0 0 0 NS NS
q. 0.015 0.006 0.017 NS NS
10T>G TT 96 (97.0%) 89 (98.9%) 120 (98.4%) NS NS
GT 3 (3.0%) 1 (1.1%) 2 (1.6%) NS NS
GG 0 0 0 NS NS
q. 0.015 0.006 0.008 NS NS
R228H* GG 97 (97.0%) 84 (98.8%) 114 (96.6%) NS NS
(G>A) AG 3 (3.0%) 1 (1.2%) 4 (3.4%) NS NS
AA 0 0 0 NS NS
q. 0.015 0.006 0.017 NS NS
LTC4S -444A>C AA 72 (72.0%) 64 (71.9%) 85 (72.6%) NS NS
AC 24 (24.0%) 23 (25.8%) 25 (21.4%) NS NS
CC 4 (4.0%) 2 (2.2%) 7 (6.0%) NS NS
q. 0.16 0.156 0.167 NS NS
Table 2. Allele and genotype frequencies of the SNPs in the candidate genes
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; n, number of patients; q, minor allele frequency. R, arginine; H, histidine;
NS, not significant. *Each p value was calculated with co-dominant, dominant and recessive models. Leukotriene Polymorphism and Aspirin-intolerant Urticaria 929
lyzed by using the Haploview version 2.05 (23).
RESULTS
The characteristics of the participants were shown in Table 1.
The three groups significantly differed with respect to age
(p<0.01 for AIU vs. AIA) and prevalence of atopy (p<0.01
for AIU vs. NC and AIU vs. AIA) between AIU and other
control groups. Seventy (77.8%) patients with AIU and 35
(43.8%) AIA patients were atopic. Patients with AIU were
composed of 31 (30.7%) chronic urticaria exacerbated by
ASA, 18 (17.8%) combined with angioedema and 4 (4.0%)
combined with anaphylaxis. Patients with both AIA and AIU
were excluded in this study.
We investigated 8 SNPs of ALOX5, ALOX5AP, PTGS2
and LTC4S in AIU compared to other control groups, AIA
and NC. Genotype distributions of all loci were in Hardy-
Weinberg equilibrium (p>0.05). Allele and genotype fre-
quencies of each SNP in four genes are shown in Table 2. Of
all SNPs tested, the polymorphism of ALOX5 at positions
of -1708 G>A showed significant difference in genotype
frequency between AIU and AIA; the frequency of minor
genotype of ALOX5-1708G>A was significantly higher in
AIU group compared to AIA group (p=0.01 in dominant
model, OR=8.9, 95% CI=1.13-10.73). The pvalue remained
significant after correction for multiple comparisons (Pc=
0.045). For all other SNPs tested, there were no significant
differences in allele and genotype frequencies among the three
groups. 
Using Haploview program, haplotypes were constructed
for 3 SNPs and the frequency of each haplotype in the patient
groups was assessed. The frequency of five haplotypes of
ALOX5 showing ≥1% frequency in the population was
shown in Table 3. There were significant differences observed
in the frequency of the ALOX5 haplotypes between the AIU
group and AIA group; the frequency of ALOX5 ht1 [G-G-
A] carrying major alleles of 3 SNPs in the AIU group was
significantly lower than that in the AIA group (p=0.01, OR=
0.541, 95% CI=0.339-0.865), but the frequencies of haplo-
types carrying minor allele of ALOX5-1708G>A, ht2 [A-
G-A] was significantly higher in AIU group compared to
AIA group (p=0.05, OR=1.697, 95% CI=1.00-2.88). Anal-
ysis of the genotype distributions of the ALOX5 haplotypes
(Table 4) also revealed that frequencies of genotype contain-
ing ht1 [G-G-A] and ht2 [A-G-A] were significantly differ-
ent between AIA and AIU (p=0.01 in dominant model for
ht1, p=0.02 in recessive model for ht2). However, there were
no differences in allele, genotype, or haplotype frequencies
of ALOX5 polymorphisms between the AIU group and the
normal control. Haplotypic analysis of PTGS2 polymorphism
was not undertaken due to the extremely low frequencies of
the variant alleles. 
AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal
controls; Ht,haplotype; N, number of chromosomes. 
*Minor alleles are given in bold.
Haplotype*
AIU
(n=196)
AIA
(n=142)
NC
(n=210)
p value
AIU vs. AIA AIU vs. NC
Ht1 (G-G-A) 0.60 0.73 0.67 0.01 0.12
Ht2 (A-G-A) 0.28 0.18 0.20 0.05 0.06
Ht3 (G-G-G) 0.08 0.03 0.05 0.06 0.22
Ht4 (G-A-A) 0.03 0.06 0.06 0.28 0.16
Ht5 (G-A-G) 0.02 0.00 0.02 0.27 0.72
Table 3. Haplotype frequencies of ALOX5 gene. The haplotype
of ALOX5 is in order of -1708G>A, 270 G>A, 1728 A>G
Ht1 Ht1/Ht1 36 (36.7%) 36 (50.7%) 46 (43.8%) 0.02 NS
Ht1/- 45 (45.9%) 32 (45.1%) 49 (46.7%) 0.01 NS
-/- 17 (17.3%) 3 (4.2%) 10 (9.5%) NS NS
Ht2 Ht2/Ht2 11 (11.2%) 1 (1.4%) 6 (5.7%) 0.04 NS
Ht2/- 32 (32.7%) 24 (33.8%) 29 (27.6%) NS NS
-/- 55 (56.1%) 46 (64.8%) 80 (65.0%) 0.01 NS
Ht3 Ht3/Ht3 0 0 0 NS NS
Ht3/- 6 (6.1%) 0 6 (5.7%) NS NS
-/- 92 (93.9%) 71 (100%) 99 (94.3%) NS NS
Ht4 Ht4/Ht4 0 0 0 NS NS
Ht4/- 6 (6.1%) 8 (11.3%) 13 (12.4%) NS NS
-/- 92 (93.9%) 63 (88.7%) 92 (87.6%) NS NS
Ht5 Ht5/Ht5 0 0 0 NS NS
Ht5/- 3 (3.1%) 0 5 (4.8%) NS NS
-/- 95 (96.9%) 71 (100%) 100 (95.2%) NS NS
Table 4. Genotype distributions of ALOX5 haplotypes 
� AIU, ASA-intolerant urticaria; AIA, ASA-intolerant asthma; NC, normal controls; Ht, haplotype. 
*Each p value was calculated with co-dominant, dominant and recessive models. 
AIU (n=98) AIA (n=71) NC (n=105)
p value*
AIU vs. AIA AIU vs. NC
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DISCUSSION
In this study, we have investigated genetic association bet-
ween polymorphisms of LT related genes (ALOX5, ALOX5-
AP, PTGS2 and LTC4S) and AIU in a Korean population.
Among 8 SNPs of four LT related genes, the polymor-
phism of ALOX5 at positions of -1708 G>A showed highly
significant differences in genotype frequency between AIU
and AIA (p=0.01). Furthermore, there were significant dif-
ferences observed in the frequency of the ALOX5 haplotypes
(ht1 and ht2) between the AIU group and AIA group. How-
ever there were no differences in allele, genotype, or haplo-
type frequencies in ALOX5 -1708 G>A between the AIU
group and the normal control. In association study of 8 SNPs
in LT related genes, ALOX5, LTC4S, PTGS2 and ALOX5AP
with phenotypes (sex, age, atopy, tIgE), we could not find
any significant difference.
In our previous study, we found that an ALOX5-ht1 [G-
C-G-A] was associated with AIA but not ASA-tolerant asth-
ma; the frequency of the ALOX5-ht1 [G-C-G-A] carrying
major alleles of these 3 SNPs in the AIA group was signifi-
cantly higher than its frequency in the control group. In addi-
tion, consistent with the present study, significant differences
in frequency of the ALOX5 polymorphism at positions of
-1708G>A was also observed between the AIU group and
the AIA group. The results of the present study however,
suggested that unlike AIA, susceptibility to AIU is associated
with minor genotype of ALOX5 -1708G>A. There was a
significant difference in atopy frequency between the AIA
and AIU groups. However this may be unlikely to influence
the results as previous studies have not identified association
of LT related polymorphism with atopy (24, 25). It may be
possible that ALOX5 polymorphism may contribute to AIU
susceptibility with odds ratio (OR) of 8.9 and 95% confi-
dence interval (95% CI) of 1.13-70.73 relative to AIA. These
results suggested that ALOX5, which catalyzes the first step
in the formation of LT, has a differing contribution in two
major clinical pathogenesis related to ASA-sensitivity. 
This study has several potential limitations. It is possible
to observe a discordant result, oral tests were postitive but the
bronchial tests were negative, according to the provocation
route (26). Our limited power to detect modest effects may
at least partially explain our modest evidence of association
to ALOX5 SNP. While the minimum p-values we observed
were modest, this is consistent with our expectations regard-
ing common, complex conditions such as AIA and AIU.
In conclusion, we have shown that ALOX5 has a differing
contribution in two major clinical pathogenesis related to
ASA-sensitivity. Our studies suggested that ALOX5 may
be a potentially important gene in AIU susceptibility in the
Korean population, and that promoter polymorphism of the
ALOX5 gene might contribute to AIU susceptibility relative
to AIA. Further studies will be needed to confirm functional
effect of the ALOX5 -1708 G>A on the pathogenic mecha-
nism of AIU. 
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